Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
![](https://investorshub.advfn.com/uicon/45965.png?cb=1637315758)
Tuesday, March 30, 2010 5:09:01 PM
1) Both were recommended by All Allan.
Now the differences:
1) All Allan recommended GNVC as part of a biotech basket, but recommended NNVC as a 5 year single stock buy and hold.
2) NNVC is in antivirals, GNVC is kind of all over the place with current focus on cancer treatments. Two indications are still in Human trials, but the Phase 3 failure adds doubt to the success of the remaining trials.
3) GNVC is developing vaccines and cancer treatments. Both require changes to the Human system to treat or vaccinate against the target disease. GNVC's technology has a whole host of problems and challenges, one of which is toxicity at therapeutic levels. NNVC's technology targets viruses and does not affect or impact the host system. In fact, there have been no indications of any toxicity or cellular damage in any of the animal trials.
4) GNVC has the backing of the NIAID and NIH through direct grants. However, its burn rate far exceeds that of NNVC, even during the early animal trials. NNVC has been unable to close on any direct government funding, but its burn rate is one-tenth that of all other biopharmas in animal studies.
5) GNVC's technology and target diseases require lengthy and expansive testing in order to demonstrate both efficacy and safety. NNVC's technology either works to target viruses or it doesn't. The gateway for approval is much earlier in the protocol; that is, if it works in Phase 1 testing there is absolutely no reason to think it won't have the same success in Phase 2 and Phase 3. For GNVC's technology, on the other hand, gateway was at the Phase 3 level where it had to demonstrate sufficient efficacy and limited toxicity in relationship to end of life diseases and extension of terminal mortality.
The comparison of the two with the intention of determining an indication of risk is a false comparison. NNVC has its own set of risks, albeit much lower risk:
1) In dealing with the FDA and the influence of Big Pharmas, the requirements and hurdles to meet standards outlined for final approval of a novel technology could delay advances and influence time lines to approval even more than they already have.
2) NNVC could fail to raise sufficient capital to complete Human testing. But, I doubt this, but it's a possibility.
3) Non-toxic nanomicelles in animals could have unexpected outcomes in Human trials. Again doubtful, but possible.
4) Human immune systems could react to nanomicelles as an invasive organism and attack the structure thus greatly reducing efficacy. Once again doubtful, yet a remote possibility.
5) The current 6 viral disease targets in development could react differently than they do in animals, even "humanized" ones, thus greatly reducing efficacy in Humans from the expectations learned from pre-clinical tests. Perhaps one might react this way, but it's highly doubtful that two much less all 6 would have the same outcome.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM